R1487 exhibits a broad spectrum of bioactivities. It shows potent inhibitory effects on a variety of kinases and proteins, including p38alpha, P38beta, ADCK3, CSNK1epsilon, DDR1, GAK, JNK1, JNK2, JNK3, NLK, RSK2, and STK36, with Kd values ranging from 0.2 nM to 1000.0 nM. It also inhibits TNF-alpha-induced IL-6 and IL-1beta production and LPS-induced TNF-alpha and IL-6 production. The compound demonstrates analgesic activity in a rat model and has favorable pharmacokinetic properties such as a Tmax of 4.67 hr, Cmax of 4016.79 nM, a half-life of 22.5 hr, an AUC of 29400.0 ng.hr.mL-1, an oral bioavailability of 51.6%, and clearance of 3.05 mL.min-1.kg-1. While it binds extensively to plasma proteins in cynomolgus monkeys, it has low aqueous solubility and permeability in human Caco-2 cells.
Additionally, R1487 reveals lower affinity for kinases such as CLK2, PLK3, CSNK1G2, PRKCZ, STK3 with Ki values exceeding 7943.28 nM, and for targets like CDC42BPA, AKT3, CDK5 with Ki values above 10000.0 nM. It shows moderate inhibitory activity against Plasmodium falciparum proliferation with potencies ranging from 9432.9 nM to 14950.2 nM. The compound has a LogD7.4 value of 2.76 and a solubility of 20400.0 nM at pH 7.4.
Importantly, R1487 demonstrates potent antiviral activity, inhibiting the SARS-CoV-2 3CL-Pro protease by 92.81% at 20µM, and reducing SARS-CoV-2 induced cytotoxicity in VERO-6 cells at 10 µM with an inhibition rate of -0.09% after 48 hours. These attributes highlight its potential as an antiviral agent, particularly against SARS-CoV-2..
Note: Summary generated by AI. Data source: ChEMBL 